Published data on transplantation in @entity8057 ( @entity8057 ) are still limited. We present a retrospective multicentric study of 27 @entity8057 @entity1 who underwent 19 autologous (median age, 54 years) and 10 allogeneic (median age, 46 years) transplantations. Median time between diagnosis and transplantation was 36 months; 66% of @entity1 had received three or more treatment lines and 72 % had chemosensitive disease. @entity34 ( @entity34 ) and autologous transplantation induced a 95% response rate (RR), including 10 major responses. With a median follow-up of 18 months, 12 @entity1 are alive at 10 to 81 months and eight are free of disease progression at 10 to 34 months. The toxic mortality rate (TRM) was 6%. Allogeneic transplantation was preceded by @entity34 in nine @entity1 and by a nonmyeloablative regimen in one @entity1 . The RR was 80%, including seven major responses. With a median follow-up of 20.5 months, six @entity1 are alive and free of progression at 3 to 76 months. Four @entity1 died, all from @entity137 , resulting in a TRM of 40%. @entity34 followed by autologous transplantation is feasible in @entity8057 , even in heavily pretreated @entity1 , with some prolonged responses but a high relapse rate. Conversely, allogeneic transplantation is more toxic, but likely induces a graft-versus- @entity8057 effect and may, for some @entity1 , result in long-term disease control.

Transplantation in XXXX --the French experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity8057 :: ('MESH:D008258', 'Disease') :: ['WM', "Waldenstrom's macroglobulinemia"] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity34 :: ('MESH:D016609', 'Disease') :: ['High-dose therapy', 'HDT']
@entity8057 :: (MESH:D008258,Disease) :: ['Waldenstrom's macroglobulinemia']
